231 related articles for article (PubMed ID: 35571176)
1. Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study.
Chang TY; Lu CT; Huang HL; Chou RH; Chang CC; Liu CT; Huang PH; Lin SJ
Front Cardiovasc Med; 2022; 9():882181. PubMed ID: 35571176
[TBL] [Abstract][Full Text] [Related]
2. Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation.
Kwon CH; Kim YJ; Kim MJ; Cha MJ; Cho MS; Nam GB; Choi KJ; Kim J
Am J Cardiol; 2022 Sep; 178():35-42. PubMed ID: 35810007
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry.
Paolisso P; Bergamaschi L; Gragnano F; Gallinoro E; Cesaro A; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Esposito G; Morici N; Andrea OJ; Casella G; Mauro C; Vassilev D; Galie N; Santulli G; Marfella R; Calabrò P; Pizzi C; Barbato E
Pharmacol Res; 2023 Jan; 187():106597. PubMed ID: 36470546
[TBL] [Abstract][Full Text] [Related]
4. Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population-Based Investigation.
Kwon O; Myong JP; Lee Y; Choi YJ; Yi JE; Seo SM; Jang SW; Kim PJ; Lee JM
J Am Heart Assoc; 2023 Jul; 12(14):e027824. PubMed ID: 37421263
[TBL] [Abstract][Full Text] [Related]
5. Treatment with SGLT2 Inhibitors in Patients with Diabetes Mellitus and Extensive Coronary Artery Disease: Mortality and Cardiovascular Outcomes.
Chipayo-Gonzales D; Shabbir A; Vergara-Uzcategui C; Nombela-Franco L; Jimenez-Quevedo P; Gonzalo N; Nuñez-Gil I; Mejia-Renteria H; Macaya-Ten F; Tirado-Conte G; Perez-Vizcayno MJ; Fuentes M; Escaned J; Fernandez-Ortiz A; Salinas P
Diabetes Ther; 2023 Nov; 14(11):1853-1865. PubMed ID: 37665429
[TBL] [Abstract][Full Text] [Related]
6. Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients.
Cai D; Chen Q; Mao L; Xiao T; Wang Y; Gu Q; Wang Q; Ji Y; Sun L
Eur J Clin Pharmacol; 2024 Apr; 80(4):613-620. PubMed ID: 38319348
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Early SGLT2 Inhibitors Initiation in Diabetic Patients Following Acute Myocardial Infarction, a Retrospective Study.
Moady G; Yakubovich I; Atar S
J Cardiovasc Pharmacol Ther; 2024; 29():10742484241252474. PubMed ID: 38711298
[TBL] [Abstract][Full Text] [Related]
8. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study.
Cesaro A; Gragnano F; Paolisso P; Bergamaschi L; Gallinoro E; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Esposito G; Morici N; Oreglia JA; Casella G; Mauro C; Vassilev D; Galie N; Santulli G; Pizzi C; Barbato E; Calabrò P; Marfella R
Front Cardiovasc Med; 2022; 9():1012220. PubMed ID: 36237914
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
Sugiyama S; Jinnouchi H; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
J Clin Med Res; 2019 Apr; 11(4):267-274. PubMed ID: 30937117
[TBL] [Abstract][Full Text] [Related]
11. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
[TBL] [Abstract][Full Text] [Related]
12. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
[TBL] [Abstract][Full Text] [Related]
13. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
14. Influence and mechanism of sodium-glucose cotransporter-2 inhibitors on the cardiac function: study protocol for a prospective cohort study.
Cao MJ; Shi FH; Yu BB; Ma XC; Zhang C; Xu L; Jiang YH; Ge H; Shen L; Pu J
Front Endocrinol (Lausanne); 2023; 14():1199960. PubMed ID: 37538793
[TBL] [Abstract][Full Text] [Related]
15. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
[TBL] [Abstract][Full Text] [Related]
17. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
Xu B; Li S; Kang B; Zhou J
Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
[TBL] [Abstract][Full Text] [Related]
18. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
19. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.
Kobayashi K; Toyoda M; Hatori N; Furuki T; Sakai H; Sato K; Miyakawa M; Tamura K; Kanamori A
J Diabetes Investig; 2021 Aug; 12(8):1408-1416. PubMed ID: 33377605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
